Edwards Lifesciences (NYSE:EW) Issues Earnings Results

Edwards Lifesciences (NYSE:EW) posted its earnings results on Thursday. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04, FiscalAI reports. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences updated its Q3 2026 guidance to 0.710-0.770 EPS and its FY 2026 guidance to 2.950-3.050 EPS.

Edwards Lifesciences Trading Down 0.9%

Shares of EW traded down $0.74 during mid-day trading on Thursday, reaching $83.63. 6,880,666 shares of the company were exchanged, compared to its average volume of 4,888,905. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences has a 52 week low of $72.30 and a 52 week high of $96.29. The business has a 50 day simple moving average of $87.65 and a two-hundred day simple moving average of $83.90. The stock has a market capitalization of $48.15 billion, a PE ratio of 44.48, a PEG ratio of 2.12 and a beta of 0.86.

Insider Activity

In related news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 45,577 shares of company stock valued at $3,855,527. 0.31% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds have recently added to or reduced their stakes in EW. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $266,000. Zions Bancorporation National Association UT increased its holdings in Edwards Lifesciences by 114.8% during the 4th quarter. Zions Bancorporation National Association UT now owns 2,099 shares of the medical research company’s stock worth $179,000 after purchasing an additional 1,122 shares in the last quarter. Imprint Wealth LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter worth approximately $108,000. Towarzystwo Funduszy Inwestycyjnych PZU SA raised its stake in shares of Edwards Lifesciences by 302.3% in the third quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 2,293 shares of the medical research company’s stock worth $178,000 after purchasing an additional 1,723 shares during the last quarter. Finally, Brown Brothers Harriman & Co. raised its stake in shares of Edwards Lifesciences by 20.9% in the third quarter. Brown Brothers Harriman & Co. now owns 1,893 shares of the medical research company’s stock worth $147,000 after purchasing an additional 327 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on EW. Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a report on Wednesday, April 1st. Evercore reiterated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research report on Monday, July 6th. Truist Financial lifted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. BTIG Research boosted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Finally, Robert W. Baird upped their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $98.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.